OBI.LSE Ondine Biomedical Inc
- Market cap
- GBX 62.8M
- P/E
- -
- P/B
- 27.31x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is OBI.LSE undervalued?
Graham numberThe Graham number of Ondine Biomedical Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Ondine Biomedical Inc fundamental analysis
No fundamental analysis for Ondine Biomedical Inc yet.
Ondine Biomedical Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Ondine Biomedical Inc
Ondine Biomedical Inc., a life-sciences company, engages in the development of activated antimicrobial therapies for the prevention and treatment of infections in Canada and internationally. Its primary product is Steriwave, a non-invasive, nurse-administered treatment that eliminates harmful bacteria, viruses, and fungi from the nose. In addition, the company offers a pipeline of photodisinfection products for various indications, including chronic sinusitis, ventilator-ass…
Full company profileOndine Biomedical Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Ondine Biomedical Inc annual financial statements
| Item | 2010 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.53M | 412K | 373K | 464K | 1.79M | 2.57M | 638K | 1.20M | 2.05M | 2.65M | 4.92M |
| Gross Profit | 1.22M | 101K | -112K | 136K | 649K | 1.25M | 287K | 703K | 1.32M | 1.09M | 2.21M |
| Operating Income | -4.18M | -5.78M | -16.5M | -14.0M | -15.9M | -17.5M | -18.8M | -14.8M | -19.4M | -30.0M | -62.9M |
| EBITDA | -3.88M | -5.45M | -15.6M | -12.6M | -14.6M | -48.4M | -18.8M | -13.8M | -18.5M | -29.4M | -61.8M |
| Net Income | -3.26M | -6.43M | -16.7M | -14.0M | -16.3M | -50.1M | -19.4M | -14.4M | -19.1M | -29.6M | -63.9M |
| EPS | -0.02 | -0.03 | -0.09 | -0.07 | -0.08 | -0.26 | -0.10 | -0.07 | -0.07 | -0.06 | -0.12 |
| Balance Sheet | |||||||||||
| Total Assets | 2.53M | 5.61M | 4.50M | 2.91M | 2.64M | 34.1M | 16.6M | 5.73M | 12.8M | 14.4M | 8.95M |
| Total Liabilities | 2.25M | 12.2M | 22.4M | 29.0M | 36.5M | 4.48M | 4.93M | 3.65M | 5.95M | 10.9M | 12.2M |
| Shareholders' Equity | 279K | -6.54M | -17.9M | -26.1M | -33.8M | 29.7M | 11.6M | 2.09M | 6.88M | 3.49M | -3.22M |
| Cash & Short-term Investments | 877K | 1.79M | 1.36M | 306K | 626K | 30.4M | 13.1M | 2.98M | 9.77M | 10.6M | 5.36M |
| Total Debt | 500K | 10.8M | 20.8M | 28.0M | 31.5M | 739K | 896K | 541K | 168K | 413K | 279K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -2.72M | -5.27M | -10.1M | -7.55M | -6.33M | -12.5M | -16.3M | -13.7M | -15.5M | -23.9M | -52.6M |
| Capital Expenditure | 180K | 433K | 134K | 33.0K | 99.0K | 77.0K | 311K | 177K | 10.0K | 117K | 447K |
| Free Cash Flow | -2.90M | -5.70M | -10.2M | -7.58M | -6.43M | -12.6M | -16.7M | -13.8M | -15.5M | -24.0M | -53.1M |
| Ratios | |||||||||||
| ROE | -1,166.6% | - | - | - | - | -168.9% | -166.4% | -691.2% | -277.7% | -848.0% | - |
| ROA | -128.5% | -114.7% | -370.3% | -480.1% | -617.5% | -146.7% | -116.9% | -251.3% | -148.9% | -205.5% | -713.6% |
| Net Profit Margin | -212.5% | -1,561.7% | -4,465.4% | -3,014.0% | -908.5% | -1,949.6% | -3,036.4% | -1,198.0% | -932.1% | -1,115.5% | -1,297.9% |
| Debt to Equity | 1.79x | - | - | - | - | 0.02x | 0.08x | 0.26x | 0.02x | 0.12x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Ondine Biomedical Inc dividends
Ondine Biomedical Inc has not paid dividends in the last 9 fiscal years.
Who owns Ondine Biomedical Inc
- Insiders 33.46%
- Institutions 30.83%
- Public & others 35.71%
- Shares outstanding 661M
- Free float 363M
Ondine Biomedical Inc company profile
- Company name
- Ondine Biomedical Inc
- Ticker
- OBI.LSE
- ISIN
- CA68234M2058
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- 1100 Melville Street, Vancouver, BC, Canada, V6E 4A6
- Phone
- 604 669 0555
- Website
- ondinebio.com
About Ondine Biomedical Inc
Ondine Biomedical Inc., a life-sciences company, engages in the development of activated antimicrobial therapies for the prevention and treatment of infections in Canada and internationally. Its primary product is Steriwave, a non-invasive, nurse-administered treatment that eliminates harmful bacteria, viruses, and fungi from the nose. In addition, the company offers a pipeline of photodisinfection products for various indications, including chronic sinusitis, ventilator-associated pneumonia, burns and other indications. Ondine Biomedical Inc. was incorporated in 1996 and is headquartered in Vancouver, Canada.
Ondine Biomedical Inc management
7- Ms. Carolyn M. Cross C.F.A., M.B.A.Founder, CEO & Executive Director
- Dr. Nicolas G. Loebel Ph.D.President, CTO & Executive Director
- Mr. Alan ThomasChief Financial Officer
- Mr. Michael AcheyVice President of Engineering & Operations
- Ms. Angelika VanceVice President of Corporate Communications
- Ms. Elaine Lei CPACorporate Controller & Company Secretary
- Mr. Nikita ParkevVP of Finance & Company Secretary